8-K: Kura Oncology Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Kura Oncology reported its second quarter 2024 financial results, highlighted by the completion of enrollment in a pivotal trial and a Breakthrough Therapy Designation for ziftomenib.

Summary

• Kura Oncology announced its second quarter 2024 financial results, reporting a net loss of $50.8 million, compared to a net loss of $37.2 million for the same period in 2023.
• Research and development expenses increased to $39.7 million from $28.2 million in the prior year's quarter, while general and administrative expenses rose to $16.7 million from $11.8 million.
• The company's cash, cash equivalents, and short-term investments totaled $491.5 million as of June 30, 2024, up from $424.0 million at the end of 2023.
• Kura completed enrollment in the Phase 2 portion of the KOMET-001 trial for ziftomenib in relapsed/refractory NPM1-mutant AML, with topline data expected in early 2025.
• The FDA granted Breakthrough Therapy Designation to ziftomenib for the treatment of R/R NPM1-mutant AML.
• The Phase 1b expansion study of KOMET-007, evaluating ziftomenib in combination with venetoclax and azacitidine or cytarabine plus daunorubicin in AML, is now enrolling patients.
• An Investigational New Drug (IND) application for ziftomenib in gastrointestinal stromal tumors (GIST) has been cleared, with a proof-of-concept study planned for the first half of 2025.
• Preclinical data suggests ziftomenib has potential in treating diabetes, showing improved insulin production and sensitivity.
• The first patient has been dosed in a study of KO-2806 and adagrasib in KRASG12C-mutated non-small cell lung cancer (NSCLC).

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with significant clinical progress and a strong cash position, although the increased net loss is a minor concern. The Breakthrough Therapy Designation and expansion into new indications are strong positives.

Positives

• The company has completed enrollment in the pivotal trial for ziftomenib in R/R NPM1-mutant AML, a significant milestone.
• The FDA granted Breakthrough Therapy Designation to ziftomenib, which could expedite its approval process.
• The company has a strong cash position of $491.5 million, which is expected to fund operations into 2027.
• The expansion of the KOMET-007 study into frontline AML treatment is a positive step.
• The clearance of the IND for ziftomenib in GIST opens up a new potential market.
• Preclinical data suggests ziftomenib has potential in treating diabetes, expanding its therapeutic applications.
• The initiation of the study of KO-2806 and adagrasib in NSCLC is a positive development for the company's pipeline.

Negatives

• The company reported a net loss of $50.8 million for the second quarter of 2024, which is an increase from the $37.2 million loss in the same period of 2023.
• Research and development expenses increased to $39.7 million, up from $28.2 million in the second quarter of 2023.
• General and administrative expenses also increased to $16.7 million, up from $11.8 million in the second quarter of 2023.

Risks

• The company's drug candidates may not demonstrate safety and efficacy in later clinical trials.
• Kura may not obtain regulatory approval to market its product candidates.
• The company relies on third parties to conduct clinical trials, which introduces risk.
• The company is dependent on outside financing to meet capital requirements.
• There are risks associated with discovering, developing, and commercializing new drugs.

Future Outlook

Kura expects its cash, cash equivalents, and short-term investments to fund current operations into 2027. The company anticipates presenting updated data from the KOMET-007 trial in Q4 2024 and topline data from the KOMET-001 trial in early 2025. They also plan to initiate a proof-of-concept study for ziftomenib in GIST in the first half of 2025 and nominate a next-generation menin inhibitor development candidate in early 2025.

Management Comments

• Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology, stated that the past quarter was highlighted by strong execution across the organization.
• He also mentioned that they are generating a robust clinical data package to support the broad development of ziftomenib.

Industry Context

Kura Oncology is operating in the competitive biopharmaceutical industry, focusing on precision medicines for cancer treatment. The company's progress with ziftomenib, particularly the Breakthrough Therapy Designation, positions it as a potential player in the AML treatment space. The expansion into GIST and diabetes indicates a broader strategy to leverage their menin inhibitor technology.

Comparison to Industry Standards

• Kura's progress with ziftomenib in AML is notable, as NPM1-mutant AML represents a significant unmet need with no approved targeted therapies, putting them ahead of many competitors in this specific niche.
• The Breakthrough Therapy Designation for ziftomenib is a positive signal, as it indicates the FDA recognizes the potential of the drug to address a serious condition, similar to other companies that have received this designation for their oncology drugs.
• The company's cash runway into 2027 is strong compared to many other clinical-stage biopharma companies, providing financial stability for ongoing research and development.
• The expansion into GIST and diabetes is a strategic move, similar to other companies that are exploring multiple indications for their drug candidates to maximize their market potential.
• The collaboration with Mirati (now Bristol Myers Squibb) for the KO-2806 study is a common practice in the industry, where companies partner to leverage each other's expertise and resources.

Stakeholder Impact

• Shareholders will be encouraged by the clinical progress and strong cash position.
• Employees will be motivated by the company's achievements and future prospects.
• Patients with AML, GIST, and diabetes may benefit from the company's drug candidates.
• The company's suppliers and partners will benefit from the ongoing research and development activities.
• Creditors will be reassured by the company's financial stability.

Next Steps

• Kura will present updated data from the KOMET-007 trial at a medical meeting in the fourth quarter of 2024.
• The company will report topline data from the KOMET-001 registration-directed trial in early 2025.
• Kura plans to present preclinical data supporting ziftomenib in GIST at a scientific meeting in the second half of 2024.
• A proof-of-concept study evaluating ziftomenib and imatinib in patients with advanced GIST will be initiated in the first half of 2025.
• The company will nominate a next-generation menin inhibitor development candidate in early 2025.
• Kura will identify the maximum tolerated dose for KO-2806 as a monotherapy in the second half of 2024.
• The company will complete enrollment of two expansion cohorts in KURRENT-HN and identify the optimal biologically active dose of tipifarnib and alpelisib by the end of 2024.
• Data from the KURRENT-HN trial will be presented in the first half of 2025.

Key Dates

Keywords

ziftomenib, AML, KOMET-001, KOMET-007, Breakthrough Therapy Designation, GIST, KO-2806, NSCLC, diabetes, menin inhibitor, clinical trials, oncology, biopharmaceutical